Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

Inclusion Criteria: 1. Provision of written informed consent 2. Male or female aged \>18 years with newly diagnosed Acute Myeloid Leukemia (AML), de novo or secondary, unfit for conventional chemotherapy 3. Male or female with Acute Myeloid Leukemia in first relapse ( \> 60 years) 4. WHO performance status ³ 2, or/and unwillingness to receive conventional chemotherapy 5. Negative pregnancy test or evidence of post-menopausal status for female patients. 6. RASGRP1/APTX gene expression ratio calculated at the screening \>10 (part B.2 only) Exclusion Criteria: 1. Serum bilirubin 2 x\> Upper Limit of Normal (ULN) 2. Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) \>3.5 x ULN 3. Serum creatinine ³ 2.5 x ULN or 24-hour creatinine clearance £ 60 mL/min (measured or calculated by Cockcroft-Gault) 4. Patients with AML of FAB M3 classification (APL) 5. Patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission 6. Any clinically defined central nervous system AML. 7. Participation in an investigational drug study within the 30 days prior to entry 8. Evidence of uncontrolled infection or CNS-Hemorrhagic 9. Patients with documented cases of human immunodeficiency virus (HIV) 10. Peripheral Neuropathy or Neuropathic Pain grade \> or = 2 11. Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used 12. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 7,NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis 13. RASGRP1/APTX gene expression ratio calculated at the screening \<10 (part B.2 only)